Single dose pharmacokinetics of syrup of ipecac

Citation
Ej. Scharman et al., Single dose pharmacokinetics of syrup of ipecac, THER DRUG M, 22(5), 2000, pp. 566-573
Citations number
37
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
THERAPEUTIC DRUG MONITORING
ISSN journal
01634356 → ACNP
Volume
22
Issue
5
Year of publication
2000
Pages
566 - 573
Database
ISI
SICI code
0163-4356(200010)22:5<566:SDPOSO>2.0.ZU;2-Z
Abstract
Syrup of ipecac (SI) has been used medicinally since the 1500s; however, li ttle is known about the pharmacokinetics in humans of SI's active ingredien ts, emetine and cephaeline. The objective of this study was to evaluate the rate of absorption and the rate of elimination of emetine and cephaeline. Ten healthy, adult, human volunteers between 18 and 45 years of age who wer e of ideal body weight (body mass index 20-25) completed this study. After an overnight fast, 30 mt SI were ingested. Blood samples were collected 30, 45, 60, 90, 120, 150, and 180 minutes post-ingestion and urine was collect ed throughout the study period. Plasma and urine concentrations of emetine and cephaeline were measured by reverse-phase HPLC with fluorescence detect ion. In virtually all subjects, emetine and cephaeline were detected within 5-10 minutes of dosing with the time to maximum concentration being approx imately 20 minutes. The mean areas under the concentration-time curve (AUC) for both emetine and cephaeline were similar; however, the ratio of mean c ephaeline maximum concentration (C-max) to emetine C-max was approximately 1.5. Four of the ten subjects exhibited a type of concentration-time profil e in which the levels of cephaeline were substantially higher than those of emetine and the levels of cephaeline were substantially higher than noted for the other six subjects. In these remaining six subjects, the levels of emetine and cephaeline were lower than 10 ng/mL at all time-points. An init ial elimination phase was noted in some subjects but nor in others. Individ uals in whom an initial elimination phase was not observed also exhibited l ow levels of both alkaloids as compared with the other subjects suggestive of a slower distribution phase. Less than 0.15% of the administered emetine and cephaeline was recovered in the urine at 3 hours. No relationship betw een vomiting episodes and peak concentrations of emetine or cephaeline was found. Administration of SI results in rapid appearance and disappearance o f emetine and cephaeline in plasma becoming almost undetectable at 3 hours. Very little of either alkaloid is eliminated in the urine within this lime period, suggesting extensive distribution. The length of time that atl adm inistered dose of SI can result in the detection of emetine and/or cephaeli ne in the urine has not been determined; future studies in humans are requi red.